Literature DB >> 30792197

Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease.

Sajida Kazi1, Abhinav Mathur2, Gwen Wilkie3, Kirsty Cheal4, Richard Battle3, Neil McGowan3, Neil Fraser4, Emily Hargreaves3, David Turner3, John D M Campbell3, Marc Turner3, Mark A Vickers5,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30792197      PMCID： PMC6669158          DOI： 10.3324/haematol.2018.207548

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

Authors:  Anne Parker; Kristin Bowles; J Andrew Bradley; Vincent Emery; Carrie Featherstone; Girish Gupte; Robert Marcus; Jayan Parameshwar; Alan Ramsay; Charles Newstead
Journal:  Br J Haematol       Date:  2010-04-16       Impact factor: 6.998

Review 2.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Authors:  Catherine M Bollard; Cliona M Rooney; Helen E Heslop
Journal:  Nat Rev Clin Oncol       Date:  2012-07-17       Impact factor: 66.675

3.  Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Michael Uhlin; Helena Wikell; Mikael Sundin; Ola Blennow; Markus Maeurer; Olle Ringden; Jacek Winiarski; Per Ljungman; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

4.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Authors:  Ekaterina Doubrovina; Banu Oflaz-Sozmen; Susan E Prockop; Nancy A Kernan; Sara Abramson; Julie Teruya-Feldstein; Cyrus Hedvat; Joanne F Chou; Glenn Heller; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Diane George; Ann Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Andromachi Scaradavou; Trudy N Small; Ramzi Khalaf; James W Young; Richard J O'Reilly
Journal:  Blood       Date:  2011-12-02       Impact factor: 22.113

5.  Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease.

Authors:  Chana Weiner; Lauren Weintraub; Birte Wistinghausen; Juli Tomaino; Ronen Arnon; Nanda Kerkar; Tamir Miloh
Journal:  Pediatr Transplant       Date:  2012-05-04

6.  A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.

Authors:  Simone Cesaro; Anna Pegoraro; Gloria Tridello; Elisabetta Calore; Marta Pillon; Stefania Varotto; Davide Abate; Luisa Barzon; Carlo Mengoli; Modesto Carli; Chiara Messina
Journal:  Transplantation       Date:  2010-06-27       Impact factor: 4.939

7.  Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

Authors:  Ralf Trappe; Stephan Oertel; Veronique Leblond; Peter Mollee; Monica Sender; Petra Reinke; Ruth Neuhaus; Hans Lehmkuhl; Heinz August Horst; Gilles Salles; Franck Morschhauser; Arnaud Jaccard; Thierry Lamy; Malte Leithäuser; Heiner Zimmermann; Ioannis Anagnostopoulos; Martine Raphael; Hanno Riess; Sylvain Choquet
Journal:  Lancet Oncol       Date:  2011-12-13       Impact factor: 41.316

8.  Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

Authors:  Jason S Knight; Alexander Tsodikov; Diane M Cibrik; Charles W Ross; Mark S Kaminski; Douglas W Blayney
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Authors:  Tanzina Haque; Gwen M Wilkie; Marie M Jones; Craig D Higgins; Gillian Urquhart; Phoebe Wingate; David Burns; Karen McAulay; Marc Turner; Christopher Bellamy; Peter L Amlot; Deirdre Kelly; Alastair MacGilchrist; Maher K Gandhi; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

Review 10.  Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Authors:  J Styczynski; H Einsele; L Gil; P Ljungman
Journal:  Transpl Infect Dis       Date:  2009-06-23       Impact factor: 2.228
View more
  9 in total

Review 1.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

2.  Sensitizing Burkitt lymphoma to EBV-CTLs.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

Review 3.  Industrializing engineered autologous T cells as medicines for solid tumours.

Authors:  Cedrik M Britten; Aiman Shalabi; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2021-04-08       Impact factor: 84.694

Review 4.  EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Authors:  Keri Toner; Catherine M Bollard
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

Review 5.  Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

Authors:  Helen E Heslop; Sandhya Sharma; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

Review 6.  Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes.

Authors:  Ayumi Fujimoto; Ritsuro Suzuki
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

7.  Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.

Authors:  Rachel S Cooper; Alasdair R Fraser; Linda Smith; Paul Burgoyne; Stuart N Imlach; Lisa M Jarvis; David M Turner; Sharon Zahra; Marc L Turner; John D M Campbell
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 8.  Could Changing the DNA Methylation Landscape Promote the Destruction of Epstein-Barr Virus-Associated Cancers?

Authors:  Alison J Sinclair
Journal:  Front Cell Infect Microbiol       Date:  2021-05-28       Impact factor: 5.293

9.  Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapy.

Authors:  Rachel S Cooper; Aleksandra Kowalczuk; Gwen Wilkie; Mark A Vickers; Marc L Turner; John D M Campbell; Alasdair R Fraser
Journal:  Clin Exp Immunol       Date:  2021-07-14       Impact factor: 5.732
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.